DE602005012382D1 - Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren - Google Patents

Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren

Info

Publication number
DE602005012382D1
DE602005012382D1 DE602005012382T DE602005012382T DE602005012382D1 DE 602005012382 D1 DE602005012382 D1 DE 602005012382D1 DE 602005012382 T DE602005012382 T DE 602005012382T DE 602005012382 T DE602005012382 T DE 602005012382T DE 602005012382 D1 DE602005012382 D1 DE 602005012382D1
Authority
DE
Germany
Prior art keywords
derived
particles
alphavirus vectors
arps
vee
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005012382T
Other languages
English (en)
Inventor
Jon O Rayner
Jonathan F Smith
Bolyn Hubby
Elizabeth A Reap
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphavax Inc
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphavax Inc filed Critical Alphavax Inc
Publication of DE602005012382D1 publication Critical patent/DE602005012382D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005012382T 2004-05-18 2005-05-18 Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren Active DE602005012382D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57221204P 2004-05-18 2004-05-18
PCT/US2005/017766 WO2005113782A1 (en) 2004-05-18 2005-05-18 Tc-83-derived alphavirus vectors, particles and methods

Publications (1)

Publication Number Publication Date
DE602005012382D1 true DE602005012382D1 (de) 2009-03-05

Family

ID=34970550

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005012382T Active DE602005012382D1 (de) 2004-05-18 2005-05-18 Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren

Country Status (16)

Country Link
US (5) US20050266550A1 (de)
EP (1) EP1751289B1 (de)
JP (1) JP5065024B2 (de)
CN (1) CN1989250B (de)
AT (1) ATE420965T1 (de)
AU (1) AU2005245956B2 (de)
CA (1) CA2567254C (de)
DE (1) DE602005012382D1 (de)
DK (1) DK1751289T3 (de)
ES (1) ES2321212T3 (de)
IL (1) IL178917A (de)
MX (1) MXPA06013124A (de)
NZ (1) NZ550818A (de)
PT (1) PT1751289E (de)
WO (1) WO2005113782A1 (de)
ZA (1) ZA200610561B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2509973C (en) 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
DE602005012382D1 (de) 2004-05-18 2009-03-05 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
WO2008085557A2 (en) 2006-09-12 2008-07-17 Alphavax, Inc. Alphavirus replicon particles encoding il- 12 as immunological adjuvants
ES2517869T3 (es) 2006-09-12 2014-11-04 Alphavax, Inc. Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos
ES2673823T3 (es) * 2006-11-03 2018-06-25 Alphavax, Inc. Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
EP2183368B1 (de) 2007-06-21 2016-08-10 Alphavax, Inc. Promotorenlose kassetten zur expression von alphavirus-strukturproteinen
WO2009048633A2 (en) * 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
WO2009051707A1 (en) * 2007-10-15 2009-04-23 Duke University Vaccine vectors
US20100010888A1 (en) * 2008-07-14 2010-01-14 Richard Maertz Methods and systems for offering purchase incentives
WO2010065414A1 (en) 2008-12-01 2010-06-10 Alphavax, Inc. Use of micrornas to control virus helper nucleic acids
WO2010118244A1 (en) 2009-04-08 2010-10-14 Alphavax, Inc. Alphavirus Replicon Particles Expressing TRP2
EP2590626B1 (de) 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomen aus lipiden, die einen vorteilhaften pka-wert zur verabreichung von rna besitzen
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
EP2591097A1 (de) 2010-07-06 2013-05-15 Novartis AG Immunogene zusammensetzungen aus norovirus und verfahren
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
PT2590676T (pt) 2010-07-06 2016-11-04 Glaxosmithkline Biologicals Sa Partículas de transferência de tipo virião para moléculas de arn auto-replicante
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
EP3542789A3 (de) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Für die liposomale freisetzung von protein-codierender rna geeignete lipide
PT4043040T (pt) 2010-08-31 2023-03-24 Glaxosmithkline Biologicals Sa Lipossomas pequenos para entrega de arn que codifica um imunogénio
PL3981427T3 (pl) 2010-08-31 2022-09-19 Glaxosmithkline Biologicals S.A. Pegylowane liposomy do dostarczania rna kodującego immunogen
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
US10004797B2 (en) * 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
JP2014520806A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム
SG10201602456WA (en) 2011-08-31 2016-04-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
WO2014108515A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
PT2970948T (pt) 2013-03-15 2019-03-20 Glaxosmithkline Biologicals Sa Métodos de purificação de arn
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
WO2015144732A2 (en) 2014-03-25 2015-10-01 Yale University Uses of parasite macrophage migration inhibitory factors
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CA2960102C (en) 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
JP2019511255A (ja) 2016-01-11 2019-04-25 バーンダリ，インク． マイクロニードル組成物およびそれを使用する方法
WO2017208191A1 (en) 2016-06-02 2017-12-07 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
BE1025121B1 (fr) 2016-11-17 2018-11-05 Glaxosmithkline Biologicals Sa Constructions antigeniques du virus zika
AU2017372731B2 (en) 2016-12-05 2024-05-23 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
WO2018194890A1 (en) * 2017-04-19 2018-10-25 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
EP3461497A1 (de) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Virale antigene
WO2019086646A1 (en) 2017-11-06 2019-05-09 Intervet International B.V. Feline leukemia virus vaccine
CA3080425A1 (en) 2017-11-06 2019-05-09 Intervet International B.V. Rabies virus vaccine
US11167027B2 (en) * 2017-11-06 2021-11-09 Intervet Inc. Multivalent feline vaccine
BR112020008958A2 (pt) 2017-11-06 2021-05-11 Intervet International B.V. vacina contra calicivírus felino
US11883476B2 (en) 2017-12-04 2024-01-30 Intervet Inc. Canine lyme disease vaccine
KR20200095479A (ko) 2017-12-04 2020-08-10 인터벳 인터내셔널 비.브이. 레플리콘 입자 및 오일 아주반트를 사용한 예방접종
JP7374893B2 (ja) * 2017-12-08 2023-11-07 インターベット インターナショナル ベー． フェー． ネコカリシウイルスワクチン
AU2018383915B9 (en) * 2017-12-15 2023-06-01 Intervet International B.V. Multivalent feline vaccine
BR112020012049A2 (pt) 2017-12-18 2020-11-24 Intervet International B.V. vacina contra vírus da influenza a suína
AU2019210189A1 (en) * 2018-01-19 2020-08-06 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
CN113164584A (zh) 2018-08-17 2021-07-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物及其用途
JP2022514307A (ja) 2018-12-20 2022-02-10 インターベット インターナショナル ベー． フェー． プライム－ブーストワクチン接種レジメン
CN109784705B (zh) * 2019-01-02 2021-07-02 中国石油天然气股份有限公司 预测产油量的方法、装置及存储介质
EP3999108A1 (de) 2019-07-21 2022-05-25 GlaxoSmithKline Biologicals S.A. Therapeutischer viraler impfstoff
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
US11730799B2 (en) 2019-10-18 2023-08-22 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
JP2023508726A (ja) 2019-12-31 2023-03-03 エリクサージェン セラピューティクス，インコーポレイティド 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達
CA3171219A1 (en) 2020-03-09 2021-09-16 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
US20230364219A1 (en) 2020-04-16 2023-11-16 Glaxosmithkline Biologicals Sa Sars cov-2 spike protein construct
CN115867658A (zh) * 2020-04-17 2023-03-28 Vlp治疗公司 冠状病毒疫苗
WO2021228731A1 (en) * 2020-05-11 2021-11-18 Intervet International B.V. Feline severe acute respiratory syndrome coronavirus 2 vaccine
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
BR112022025678A2 (pt) 2020-06-19 2023-01-17 Intervet Int Bv Vacina contra o vírus da influenza a suína compreendendo duas partículas de replicon de rna distintas
WO2021255219A1 (en) 2020-06-19 2021-12-23 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct having a specific order of genes
JP2023534900A (ja) 2020-06-19 2023-08-15 ジフィウス ヴァクシーンス 自己増幅ｓａｒｓ－ｃｏｖ－２ｒｎａワクチン
EP4168428A1 (de) 2020-06-19 2023-04-26 Intervet International B.V. Schweineinfluenza-a-virus-impfstoff mit einem nukleinsäurekonstrukt zur codierung von antigenen spezifischer viruslinien
CN115768785A (zh) 2020-06-19 2023-03-07 英特维特国际股份有限公司 包含含有编码病毒的不同神经氨酸酶抗原的第一、第二和第三核酸序列的核酸构建体的甲型猪流感病毒疫苗
US20230256090A1 (en) 2020-06-29 2023-08-17 Glaxosmithkline Biologicals Sa Adjuvants
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
JP2023539771A (ja) 2020-09-07 2023-09-19 インターベット インターナショナル ベー． フェー． Ｈａ抗体陽性ターゲットのためのｈａステムワクチン
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
AU2021378483A1 (en) 2020-11-12 2023-06-08 Intervet International B.V. Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof
EP4267593A2 (de) 2020-12-23 2023-11-01 GlaxoSmithKline Biologicals SA Selbstverstärkende messenger-rna
EP4032546A1 (de) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Therapeutischer viraler impfstoff
US20240181038A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4346894A1 (de) 2021-05-24 2024-04-10 GlaxoSmithKline Biologicals S.A. Adjuvans
IL309408A (en) 2021-06-18 2024-02-01 Sanofi Sa Multivalent flu vaccines
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
EP4387597A1 (de) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Gefriertrocknung von lipidnanopartikeln (lnps) zur verkapselung von rna und formulierungen davon
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
EP4387596A1 (de) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Lyophilisierte rna-impfstoffe mit niedriger dosis und verfahren zur herstellung und verwendung davon
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
AU2022337090A1 (en) 2021-09-03 2024-02-15 Glaxosmithkline Biologicals Sa Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
CN118139640A (zh) 2021-10-25 2024-06-04 英特维特国际股份有限公司 保护仔猪抵抗甲型猪流感病毒感染的疫苗
CN118215472A (zh) 2021-11-02 2024-06-18 纪费亚斯公司 用于寡核苷酸递送的脂质纳米颗粒
WO2023078950A1 (en) 2021-11-02 2023-05-11 Ziphius Vaccines Nv Lipid nanoparticles for oligonucleotide delivery
WO2023078954A1 (en) 2021-11-02 2023-05-11 Ziphius Vaccines Nv Lipid nanoparticles for oligonucleotide delivery
AR127585A1 (es) 2021-11-05 2024-02-07 Sanofi Sa Vacuna de arn de virus sincicial respiratorio
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
US11730804B1 (en) * 2022-04-13 2023-08-22 Replicate Bioscience, Inc. Compositions and methods for the prevention and treatment of rabies virus infection
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
WO2024044108A1 (en) 2022-08-22 2024-02-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against coronaviruses
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
AU6172194A (en) * 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US20020102273A1 (en) * 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ES2328424T3 (es) 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. Vectores de alfavirus recombinantes.
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5639650A (en) * 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
IL127692A0 (en) * 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
US5827658A (en) * 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5726022A (en) * 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
ATE550429T1 (de) * 1996-11-20 2012-04-15 Crucell Holland Bv Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) * 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
DE69942006D1 (de) 1998-04-08 2010-03-25 Univ North Carolina Krebsimpfstoff enthaltend alphavirusrepliconpartikeln
EP1080218A1 (de) * 1998-05-27 2001-03-07 University of Florida Methode zur darstellung von rekombinanten adeno-assoziierten virus zusammensetzungen mit hilfe von iodixanol gradienten
CA2336587A1 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
JP3585778B2 (ja) * 1998-09-25 2004-11-04 株式会社白子 海苔の酵素分解組成物およびその用途
JP2002526421A (ja) * 1998-10-05 2002-08-20 ジェンザイム・コーポレーション 癌細胞に差別的に発現する癌ワクチン設計のための遺伝子
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
ATE465266T1 (de) * 1998-12-31 2010-05-15 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
EP1175497B1 (de) 1999-04-14 2010-04-07 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
ATE324877T1 (de) 1999-08-17 2006-06-15 Purdue Research Foundation Behandlung von metastatischer krankheit
WO2001031046A1 (en) * 1999-10-26 2001-05-03 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
DE60135983D1 (de) * 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
AU2001273313A1 (en) * 2000-07-07 2002-01-21 Alphavax, Inc. Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
WO2002080982A2 (en) * 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
ES2345876T3 (es) * 2001-05-31 2010-10-05 Novartis Vaccines And Diagnostics, Inc. Particulas de replicones de alfavirus quimericos.
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
US6605947B2 (en) * 2001-10-03 2003-08-12 Yi-Chia Liao Cup shape sensible container for detecting liquid property
JP3857195B2 (ja) * 2002-07-09 2006-12-13 株式会社東芝 距離継電装置
CA2509973C (en) * 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
DK3246399T3 (da) * 2002-12-13 2021-10-04 Alphavax Inc Alfavirus-partikler og fremgangsmåder til fremstilling
KR101454842B1 (ko) 2003-03-20 2014-11-04 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
DE602005012382D1 (de) 2004-05-18 2009-03-05 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines

Also Published As

Publication number Publication date
US9079943B2 (en) 2015-07-14
EP1751289B1 (de) 2009-01-14
MXPA06013124A (es) 2007-05-23
US20140205629A1 (en) 2014-07-24
EP1751289A1 (de) 2007-02-14
CA2567254C (en) 2012-03-13
US20110027306A1 (en) 2011-02-03
IL178917A0 (en) 2007-03-08
CA2567254A1 (en) 2005-12-01
US9441247B2 (en) 2016-09-13
US20150299728A1 (en) 2015-10-22
AU2005245956A1 (en) 2005-12-01
ZA200610561B (en) 2008-06-25
DK1751289T3 (da) 2009-05-11
US10570416B2 (en) 2020-02-25
ES2321212T3 (es) 2009-06-03
JP2007537761A (ja) 2007-12-27
US20050266550A1 (en) 2005-12-01
AU2005245956B2 (en) 2011-05-19
US8709441B2 (en) 2014-04-29
US20160348132A1 (en) 2016-12-01
NZ550818A (en) 2009-09-25
JP5065024B2 (ja) 2012-10-31
CN1989250A (zh) 2007-06-27
ATE420965T1 (de) 2009-01-15
PT1751289E (pt) 2009-03-31
WO2005113782A1 (en) 2005-12-01
IL178917A (en) 2010-11-30
CN1989250B (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
DE602005012382D1 (de) Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
DE602005014628D1 (de) Embolie-teilchen
ATE409749T1 (de) Verfahren zur reinigung von alphaviralen replikon partikeln
MY178870A (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
DE60236864D1 (de) Chimere alphavirus-replikon-partikel
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
DE602005015102D1 (de) Wässrige dispersionen von silikon-polyether-blockcopolymeren
SG156666A1 (en) Vaccines against japanese encephalitis virus and west nile virus
MX2017002791A (es) Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
EP2525816A4 (de) Gerichtete präsentation eines heterologen antigens auf calicivirusähnlichen partikeln
EP1594536A4 (de) Adjuvante influenza-vakzine
BRPI0516576A (pt) vetores quiméricos
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
MX2017002890A (es) Métodos y composiciones para potenciar respuestas inmunitarias.
MX2020011586A (es) Virus vaccinia quimerico sintetico.
DK1476860T3 (da) Fremgangsmåde til definition af en gruppe mellem bidirektionelle gen-stande
MX2023004078A (es) Proteinas f de hmpv estabilizadas por prefusion.
WO2004005473A3 (en) Hcv fusion proteins with modified ns3 domains
MXPA05008859A (es) Composiciones adhesivas antiplaca para dentaduras.
NZ631012A (en) Compositions and methods for live, attenuated alphavirus formulations
WO2012045063A3 (en) Flavivirus domain iii vaccine
DE602004029075D1 (de) Verwendung von knotenholzextrakten
WO2006073422A3 (en) Activation of natural killer (nk) cells and methods of use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition